Bank of Montreal
SUPN icon

Bank of Montreal’s Supernus Pharmaceuticals SUPN Stock Holding History

Bank of Montreal’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,200
Closed -$408K – 4016
2025
Q4 		$408K Buy
+8,200
New +$399K ﹤0.01% 2413
2013
Q4 		– Sell
-20,000
Closed -$147K – 3915
2013
Q3 		$147K Buy
+20,000
New +$134K ﹤0.01% 2364

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal's SUPN Position: Q1 2026 in Review

Bank of Montreal increased its Supernus Pharmaceuticals (SUPN) stake by 20% in Q1 2026, buying an estimated $52.6K and bringing the position to 6,312 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #2622.

Bank of Montreal first reported a position in SUPN in Q2 2013 and has held it in 48 quarters since. The position peaked at $4.78M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Bank of Montreal held 6,312 shares of Supernus Pharmaceuticals worth $326K as of Q1 2026.
  • Bank of Montreal bought 1,033 Supernus Pharmaceuticals shares in Q1 2026, an estimated $52.6K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #2622 holding.
  • Bank of Montreal first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • Bank of Montreal's Supernus Pharmaceuticals position peaked at $4.78M in Q2 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.